2016 Half-Year Results
Corporate
Pharma&Biotech –
Clinical Development and Bioscience
Lonza
Pharma&
Biotech
B2B
4
& BIOTECH
PHARMA&
Commercial Manufacturing,
Clinical Development Services,
Products (Consumables,
Tests, Media, Equipment)
Clinical Development Services
■Clinical Development & Licensing (CDL) business
ahead of market growth benefiting from continued
strong demand for tier 1 CMO development and
manufacturing services
■ Emerging Technologies with strong growth
success of changing business models seen in
the long-term agreement with bluebird bio, Inc.
■New Drug Product Services facility is set to open
its doors in Basel in the fourth quarter of 2016
Bioscience Solutions / Products
■Market demand favorable; delivered solid growth
compared with the same period last year
10
Jul-16
2016 Half-Year Results - 20 July 2016View entire presentation